Turn Therapeutics (TTRX) Cash from Financing Activities (2024 - 2026)

Turn Therapeutics' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $7.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 680.14% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $12.5 million (changed N/A YoY), while the FY2025 annual figure was $6.9 million, up 500.45% from the prior year.
• Cash from Financing Activities was $7.8 million for Q1 2026 at Turn Therapeutics, up from $3.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.8 million in Q1 2026 to a low of $522206.0 in Q4 2024.
• Historically, Cash from Financing Activities has averaged $3.1 million across 3 years, with a median of $2.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities jumped 508.51% in 2025, then surged 680.14% in 2026.
• A 3-year view of Cash from Financing Activities shows it stood at $522206.0 in 2024, then surged by 508.51% to $3.2 million in 2025, then surged by 145.04% to $7.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.8 million (Q1 2026), $3.2 million (Q4 2025), and $998092.0 (Q1 2025), per Business Quant data.